Skip To Main Content
Yindan Lin on Muck Rack

Yindan Lin

As seen in: ACS Publications, BioRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yindan

Contact Yindan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

EZH2 Inhibition Boosts Tumor Immunogenicity and TIL Reactivity in Lung Cancer

|
By Daniel R Plaugher, Yindan Lin, Christian M Gosser
| BioRxiv
Abstract Lung cancer, the leading cause of cancer-related death in the United States, remains a significant public health burden. One of the most personalized treatments to date uses a patient's own tumor-infiltrating lymphocytes (TILs) as a cellular therapy to target the tumor. Endogenous TIL activity is also essential for immune checkpoint inhibitor (ICI) effectiveness.
Open in Who Shared Issue with article?

Design, Synthesis, and Evaluation of p53Y220C Acetylation Targeting Chimeras (AceTACs)

|
By Xiaoping Hu, Yan Xiong, Ramon Parsons, Yindan Lin
| ACS Publications
Introduction Click to copy section linkSection link copied! The transcription factor p53, a well-known tumor suppressor, plays a key role in the regulation of cellular processes, including cell cycle, DNA repair, apoptosis, and epigenetic control of gene expression. (1−3) In about 50% of all human cancers, p53 is functionally abolished or altered via mutation.
Open in Who Shared Issue with article?

Design, Synthesis, and Evaluation of p53Y220C Acetylation Targeting Chimeras (AceTACs)

|
By Xiaoping Hu, Yindan Lin, Yan Xiong, Ramon Parsons
| dx.doi.org
Open in Who Shared Issue with article?
See all 3 articles